Zelira Therapeutics Ltd has released a press release.
Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Appendix 4E and Financial Report to Shareholders
- June 2024 Quarterly Activities Report
- ZLD Advances HOPE Autism Drug Program with U.S FDA Meeting
- ZLD secures US$1.4M unsecured Chairman loan facility
- HOPE SPV receives US$681,000 third tranche of funding
Later from Zelira Therapeutics
- Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche
- Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund
- Appendix 4D & FY25 Interim Financial Report
- Zelira secures $1 Million At-the-Market Funding Facility
- Publication of ZLT-L-007 IRB Approved Observational Study
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics